DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening ...

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...

Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) reported new clinical data from its ...

Following up on its landmark FDA clearance for pediatric use earlier this month, Dexcom is backing up its newly expanded hardware reach with an AI-driven app overhaul. Unveiled at the Aspen Ideas: ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

Children may experience shorter sensor wear times due to physical and behavioral differences. The Food and Drug Administration (FDA) has cleared Dexcom’s Stelo Glucose Biosensor System for children ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom received FDA clearance for its first over-the-counter continuous glucose monitor, called Stelo. The device is intended for ...